KYTHERA BIOPHARMACEUTICALS INC 4
4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Oct 2, 2015
Insider Transaction Report
Form 4
Klein Keith
General Counsel
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2015-10-01−28,960→ 0 totalExercise: $4.50Exp: 2018-09-16→ Common Stock (28,960 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−21,272→ 0 totalExercise: $5.90Exp: 2020-10-14→ Common Stock (21,272 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−852→ 0 totalExercise: $8.22Exp: 2022-02-01→ Common Stock (852 underlying) - Disposition to Issuer
Common Stock
2015-10-01−4,643→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−15,608→ 0 totalExercise: $44.02Exp: 2024-01-22→ Common Stock (15,608 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−13,614→ 0 totalExercise: $4.84Exp: 2019-01-21→ Common Stock (13,614 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−6,700→ 0 totalExercise: $27.50Exp: 2023-01-29→ Common Stock (6,700 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−36,758→ 0 totalExercise: $38.53Exp: 2025-01-29→ Common Stock (36,758 underlying)
Footnotes (9)
- [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement" and the transactions contemplated therein, the "Merger"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
- [F2]Includes 575 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on September 21, 2015.
- [F3]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 7,654 shares of Allergan common stock at an exercise price of $17.00 per share.
- [F4]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 3,598 shares of Allergan common stock at an exercise price of $18.30 per share.
- [F5]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 5,622 shares of Allergan common stock at an exercise price of $22.31 per share.
- [F6]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 225 shares of Allergan common stock at an exercise price of $31.11 per share.
- [F7]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 1,770 shares of Allergan common stock at an exercise price of $104.04 per share.
- [F8]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 4,125 shares of Allergan common stock at an exercise price of $166.55 per share.
- [F9]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 9,715 shares of Allergan common stock at an exercise price of $145.78 per share.